How is breast cancer staged using the TNM system?

Breast Cancer Staging Using the TNM System

Breast cancer is staged using the AJCC TNM system, which combines anatomic factors (Tumor size, lymph Node involvement, and distant Metastases) with biologic markers (ER/PR status, HER2 expression, and tumor grade) to create prognostic stage groups that more accurately predict outcomes than anatomic staging alone. 1, 2

Core TNM Components

T (Primary Tumor)

The tumor classification is based on size and local extension 1, 3:

• Tis: Carcinoma in situ (DCIS, LCIS, or Paget's disease without underlying invasive cancer)
• T1: Tumor ≤20 mm
  • T1mi: ≤1 mm (microinvasion)
  • T1a: >1 mm but ≤5 mm
  • T1b: >5 mm but ≤10 mm
  • T1c: >10 mm but ≤20 mm
• T2: Tumor >20 mm but ≤50 mm
• T3: Tumor >50 mm
• T4: Any size with chest wall extension and/or skin involvement
  • T4a: Chest wall extension (excluding pectoralis muscle)
  • T4b: Skin ulceration, satellite nodules, or edema (peau d'orange)
  • T4c: Both T4a and T4b
  • T4d: Inflammatory breast cancer

N (Regional Lymph Nodes)

Lymph node staging has become increasingly complex with modern detection methods 4:

Key nodal staging principles:

• Isolated tumor cells (≤0.2 mm): Designated as pN0(i+) whether detected by H&E or IHC
• Micrometastases (>0.2 mm but ≤2.0 mm): Designated as pN1mi
• Number of involved nodes determines pathologic N stage:
  • pN1: 1-3 lymph nodes involved
  • pN2: 4-9 lymph nodes involved
  • pN3: ≥10 lymph nodes involved

Critical anatomic considerations:

• Infraclavicular nodes: Categorized as N3 disease
• Internal mammary (IM) nodes: Staging depends on detection method
  • N1: IM nodes detected exclusively by sentinel lymph node procedure
  • N2: IM nodes detected by imaging or clinical examination
  • N3: IM nodes with concomitant axillary involvement
• Supraclavicular nodes: Now classified as N3 (no longer M1 disease) 4

M (Distant Metastases)

• M0: No distant metastases
• M1: Distant metastases present

Integration of Biologic Factors

The eighth edition AJCC staging system represents a paradigm shift by incorporating tumor biology into prognostic staging 5, 6, 7. This creates two parallel staging systems:

Anatomic Stage Group

Based solely on TNM factors—maintained for continuity and regions where biomarkers are unavailable 6, 8

Prognostic Stage Groups

Incorporates 5, 6, 8:

• Tumor grade (histologic differentiation)
• ER status (estrogen receptor expression)
• PR status (progesterone receptor expression)
• HER2 status (amplification/overexpression)
• Multigene panel scores (when available, such as Oncotype DX)

Clinical impact: Applying prognostic stage groups changed the stage grouping for approximately 40% of patients compared to anatomic staging alone, providing more precise individual prognostication 8

Stage Groupings

The traditional stage groupings remain, with one important addition 4:

• Stage 0: Tis, N0, M0
• Stage I-IIA: Early disease with limited nodal involvement
• Stage IIB-IIIA: Locally advanced disease
• Stage IIIB: Includes T4 disease or inflammatory breast cancer (T4d, any N, M0) 9
• Stage IIIC: Created specifically for T any, N3, M0 disease (recognizing the poor prognosis of extensive nodal involvement)
• Stage IV: Any T, any N, M1

Clinical Application Algorithm

For initial staging:

1. Obtain clinical TNM (cTNM) through physical examination and imaging before any treatment 2
2. Perform core needle biopsy to establish diagnosis and assess biomarkers (ER, PR, HER2, grade) 3
3. Assess distant metastases only for:
   • Stage IIB or higher disease
   • Clinically positive axillary nodes
   • Large tumors (≥5 cm)
   • Symptomatic patients or abnormal laboratory values 3, 2

For definitive staging:

1. Obtain pathologic TNM (pTNM) from surgical specimens 1, 3

2. Document all required pathologic elements:

   • Number and location of tumors
   • Total lymph nodes examined and number positive
   • Size of nodal metastases (isolated tumor cells vs. micrometastases vs. macrometastases)
   • Histologic type and grade
   • Surgical margin status
   • Lymphovascular invasion
   • Complete biomarker panel (ER, PR, HER2)

3. Apply prognostic stage grouping using combined anatomic and biologic factors 6, 8

Critical Pitfalls to Avoid

Lymph node assessment errors:

• Failing to distinguish between isolated tumor cells (pN0[i+]) and micrometastases (pN1mi)—this distinction affects staging and may influence treatment decisions 4
• Not documenting the detection method for internal mammary nodes (sentinel vs. imaging/clinical), which changes N classification 4

Biomarker reporting failures:

• Up to 50% of pathology reports historically miss critical elements 4
• Always verify ER, PR, and HER2 status are documented—these are mandatory for prognostic staging 1, 3
• If biomarkers are negative on core biopsy, retest on surgical specimen due to tumor heterogeneity 3

Stage migration:

• Recognize that prognostic stage may differ substantially from anatomic stage—a patient with favorable biology (ER+/PR+/HER2-/low grade) and limited anatomic disease may have a lower prognostic stage than anatomic stage suggests 5, 8

The modern TNM staging system for breast cancer thus provides a flexible, evidence-based framework that integrates traditional anatomic factors with contemporary understanding of tumor biology to optimize prognostic accuracy and treatment planning 6, 7.